A mutational process signature and genomic alterations associated with outcome and immunogenicity in cancers with brain metastasis.

Front Immunol · 2025 · PMC12343737 · PMID 40808963

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

failed to reach statistical significanceno p-value reported

Besides, in the stratified analyses of our study, we found that both mutational signature 6, cluster 3, and PTPRT mutation maintained their original prognostic capabilities in NSCLC/SKCM/BRCA patients, but failed to reach statistical significance in other primary tumor types with a smaller proportion (~30%).

also in 6,035 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.